AAP
DMII

Arax Advisory Partners’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

Arax Advisory Partners’s Portfolio DMII Stock Details DMII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$664K Buy
+65,990
New +$662K ﹤0.01% 1449

Other funds holding DMII

WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.66% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
MCS
Mercuria Capital Strategies Houston, Texas $163M AUM 258.7% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.34% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
DWM
Dakota Wealth Management Palm Beach Gardens, Florida $5.24B AUM 38.12% 1-Year Est. Return
TCM
Tuttle Capital Management Riverside, Connecticut $148M AUM 64.14% 1-Year Est. Return

Arax Advisory Partners's DMII Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Drugs Made In America Acquisition II Corp (DMII) in Q2 2026: 65,990 shares worth $664K. The stake represents ﹤0.01% of the portfolio and ranks #1449 among its holdings.

11 funds tracked by Wall St. Rank hold DMII as of Q2 2026.

  • Arax Advisory Partners held 65,990 shares of Drugs Made In America Acquisition II Corp worth $664K as of Q2 2026.
  • Drugs Made In America Acquisition II Corp was a new Arax Advisory Partners position in Q2 2026.
  • Drugs Made In America Acquisition II Corp made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1449 holding.
  • 11 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.